James Condulis

Stock Analyst at Stifel Nicolaus

(3.32)
# 2,479
Out of 4,703 analysts
56
Total ratings
53.2%
Success rate
7.2%
Average return

Stocks Rated by James Condulis

Arrowhead Pharmaceuticals
Aug 31, 2026
Maintained: Buy
Price Target: $104
Current: $86.34
Upside: +20.45%
Braveheart Bio
Aug 31, 2026
Initiated Coverage: Buy
Price Target: $45
Current: $26.74
Upside: +68.29%
Amylyx Pharmaceuticals
Aug 18, 2026
Reiterated: Buy
Price Target: n/a
Current: $34.10
Upside: -
Aardvark Therapeutics
Aug 13, 2026
Reiterated: Hold
Price Target: $6
Current: $5.38
Upside: +11.52%
Edgewise Therapeutics
Aug 11, 2026
Maintained: Hold
Price Target: $36
Current: $43.07
Upside: -16.42%
Cytokinetics
Aug 7, 2026
Reiterated: Buy
Price Target: $108
Current: $72.72
Upside: +48.51%
X4 Pharmaceuticals
Aug 7, 2026
Maintained: Buy
Price Target: $10
Current: $4.04
Upside: +147.52%
Tectonic Therapeutic
Aug 7, 2026
Maintained: Buy
Price Target: $75
Current: $30.75
Upside: +143.90%
Mirum Pharmaceuticals
Aug 6, 2026
Maintained: Buy
Price Target: $136
Current: $100.90
Upside: +34.79%
NewAmsterdam Pharma Company
Aug 6, 2026
Reiterated: Buy
Price Target: $50
Current: $25.40
Upside: +96.85%
Downgraded: Hold
Price Target: $25$3
Current: $3.85
Upside: -22.08%